Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial

[1]  J. Cuzick,et al.  Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial , 2014, The Lancet.

[2]  A. LaCroix,et al.  Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data , 2013, The Lancet.

[3]  R. Kay.  The Analysis of Survival Data , 2012 .

[4]  R Peto,et al.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[5]  Early Breast Cancer Trialists' Collaborative Group.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[6]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[7]  B. Bonanni,et al.  Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. , 2007, Journal of the National Cancer Institute.

[8]  J. Cuzick,et al.  Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. , 2007, Journal of the National Cancer Institute.

[9]  T. Powles,et al.  Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. , 2007, Journal of the National Cancer Institute.

[10]  L. Ford,et al.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.

[11]  J Cuzick,et al.  Overview of the main outcomes in breast-cancer prevention trials , 2003, The Lancet.

[12]  P. Boyle,et al.  Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. , 2003, Journal of the National Cancer Institute.

[13]  M Baum,et al.  First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial , 2002, The Lancet.

[14]  W. Gradishar,et al.  Tamoxifen and contralateral breast cancer. , 1999, Journal of the American College of Surgeons.

[15]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[16]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[17]  T. Powles,et al.  Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.

[18]  P. Boyle,et al.  Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women , 1998, The Lancet.

[19]  V. Kyle,et al.  PROSTAGLANDIN E1 AND PERIPHERAL VASCULAR DISEASE , 1983, The Lancet.

[20]  David A. Schoenfeld,et al.  Chi-squared goodness-of-fit tests for the proportional hazards regression model , 1980 .

[21]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[22]  D.,et al.  Regression Models and Life-Tables , 2022 .